Organisation paid for research Program year 2025 Source: CMS Open Payments

Alpine Clinical Research Center

Neither a doctor nor a teaching hospital

Research payments

$10,828,245

211 payments

Through program year 2025, Alpine Clinical Research Center is reported as receiving $10,828,245 in research payments, across 211 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,740,653 5
2024 Research $1,485,969 34
2023 Research $1,590,830 5
2022 Research $2,229,290 13
2021 Research $1,748,445 74
2020 Research $1,414,780 47
2019 Research $618,278 33

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $9,609,479 22 payments
  2. Allergan Inc. $902,054 100 payments
  3. AbbVie, Inc. $120,342 46 payments
  4. Sanofi US Services Inc. $99,599 30 payments
  5. AstraZeneca Pharmaceuticals LP $82,440 2 payments
  6. Chiesi USA, Inc. $7,206 3 payments
  7. Pfizer Inc. $1,785 1 payment
  8. Currax Pharmaceuticals LLC $1,600 2 payments
  9. Avanir Pharmaceuticals, Inc. $1,463 1 payment
  10. Amgen Inc. $1,213 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $8,738,946 9 payments
  2. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $424,785 5 payments
  3. A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod Baf312 in Patients With Secondary Progressive Multiple Sclerosis $296,444 3 payments
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $292,552 25 payments
  5. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine $169,684 21 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $146,914 16 payments
  7. A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 MG Subcutaneous Ofatumumab Injected By Pre-Filled Syringe Or Autoinjector in Adult RMS Patients $130,712 1 payment
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $119,274 11 payments
  9. A Phase 3, Multicenter, Open-Label 52-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Chronic Or Episodic Migraine $100,172 12 payments
  10. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $82,440 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record